Loading...
•
Mar 31, 2021
Bausch Health Q1 2021 Earnings Report
Bausch Health reported mixed Q1 2021 results, with revenue slightly increasing and a net loss reported.
Key Takeaways
Bausch Health reported a slight increase in revenue for Q1 2021, but experienced a significant net loss due to goodwill impairment charges. The company is progressing with the planned separation of its eye health business, Bausch + Lomb, and reaffirmed its full-year revenue and adjusted EBITDA guidance.
Total revenues increased by 1% to $2.027 billion compared to Q1 2020.
GAAP net loss was $610 million, primarily due to a goodwill impairment charge.
Adjusted EBITDA (non-GAAP) increased to $852 million from $813 million in Q1 2020.
The company continues to advance its plan to spin off the Bausch + Lomb eye health business.
Revenue by Segment
Forward Guidance
Bausch Health reiterated guidance for the full year of 2021 with revenue range of $8.60 – $8.80 billion and Adjusted EBITDA range of $3.40 – $3.55 billion.
Positive Outlook
- Full-year revenue range of $8.60 – $8.80 billion
- Full-year Adjusted EBITDA (non-GAAP) range of $3.40 – $3.55 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...